Maucher A, von Angerer E, Hampl R, Stárka L
Institut für Pharmazie, Universität Regensburg, Germany.
Endocr Regul. 1994 Mar;28(1):23-9.
Epitestosterone has been shown previously to counteract the testosterone activity in some experimental models. In the present study the activity of epitestosterone in an in vitro model of human LNCaP/FCS prostate cells and in vitro in Dunning R 3327-GH rat prostate carcinoma was tested. In LNCaP/FGC cells cultivated with fetal calf serum (FCS) treated with dextran-coated charcoal epitestosterone displayed rather androgenic than antiandrogenic properties, whereas the cultivation with native FCS resulted in a very weak inhibition of tumour cell growth with epitestosterone in higher concentration. The growth of Dunning R 3327-GH carcinoma of prostate was very weakly enhanced by epitestosterone alone as late as at the end of the 5-week experiment. Epitestosterone did not significantly inhibit the testosterone stimulated tumour growth.